vs

Side-by-side financial comparison of INTERNATIONAL BANCSHARES CORP (IBOC) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

INTERNATIONAL BANCSHARES CORP is the larger business by last-quarter revenue ($217.7M vs $186.7M, roughly 1.2× NEOGENOMICS INC). INTERNATIONAL BANCSHARES CORP runs the higher net margin — 62.3% vs -57.9%, a 120.2% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 4.5%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs 2.8%).

International Bancshares Corporation is a bank holding company based in Laredo, Texas whose primary subsidiary is International Bank of Commerce. Through its bank subsidiaries, it has 217 banking offices and 315 automated teller machines serving 88 communities in the U.S. states of Texas and Oklahoma.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

IBOC vs NEO — Head-to-Head

Bigger by revenue
IBOC
IBOC
1.2× larger
IBOC
$217.7M
$186.7M
NEO
Growing faster (revenue YoY)
NEO
NEO
+6.6% gap
NEO
11.1%
4.5%
IBOC
Higher net margin
IBOC
IBOC
120.2% more per $
IBOC
62.3%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
2.8%
IBOC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBOC
IBOC
NEO
NEO
Revenue
$217.7M
$186.7M
Net Profit
$106.9M
$-108.0M
Gross Margin
43.3%
Operating Margin
62.8%
46.9%
Net Margin
62.3%
-57.9%
Revenue YoY
4.5%
11.1%
Net Profit YoY
-7.1%
42.0%
EPS (diluted)
$1.71
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBOC
IBOC
NEO
NEO
Q1 26
$186.7M
Q4 25
$217.7M
$190.2M
Q3 25
$218.1M
$187.8M
Q2 25
$208.2M
$181.3M
Q1 25
$198.2M
$168.0M
Q4 24
$208.3M
$172.0M
Q3 24
$211.8M
$167.8M
Q2 24
$207.8M
$164.5M
Net Profit
IBOC
IBOC
NEO
NEO
Q1 26
$-108.0M
Q4 25
$106.9M
Q3 25
$108.4M
$-27.1M
Q2 25
$100.1M
$-45.1M
Q1 25
$96.9M
$-25.9M
Q4 24
$115.1M
Q3 24
$99.8M
$-17.7M
Q2 24
$97.0M
$-18.6M
Gross Margin
IBOC
IBOC
NEO
NEO
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
IBOC
IBOC
NEO
NEO
Q1 26
46.9%
Q4 25
62.8%
-7.1%
Q3 25
62.6%
-14.4%
Q2 25
60.5%
-26.3%
Q1 25
61.1%
-16.6%
Q4 24
64.2%
-10.7%
Q3 24
60.0%
-12.6%
Q2 24
60.1%
-13.3%
Net Margin
IBOC
IBOC
NEO
NEO
Q1 26
-57.9%
Q4 25
62.3%
Q3 25
49.7%
-14.4%
Q2 25
48.1%
-24.9%
Q1 25
48.9%
-15.4%
Q4 24
71.5%
Q3 24
47.1%
-10.5%
Q2 24
46.7%
-11.3%
EPS (diluted)
IBOC
IBOC
NEO
NEO
Q1 26
$-0.13
Q4 25
$1.71
Q3 25
$1.74
Q2 25
$1.61
Q1 25
$1.56
Q4 24
$1.85
Q3 24
$1.60
Q2 24
$1.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBOC
IBOC
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$5.5B
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.3B
$828.8M
Total Assets
$16.6B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBOC
IBOC
NEO
NEO
Q1 26
$146.1M
Q4 25
$5.5B
$159.6M
Q3 25
$5.6B
$164.1M
Q2 25
$5.8B
$154.7M
Q1 25
$5.6B
$346.2M
Q4 24
$5.4B
$367.0M
Q3 24
$5.8B
$362.0M
Q2 24
$5.7B
$355.1M
Total Debt
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
IBOC
IBOC
NEO
NEO
Q1 26
$828.8M
Q4 25
$3.3B
$836.6M
Q3 25
$3.1B
$838.3M
Q2 25
$3.0B
$854.0M
Q1 25
$2.9B
$888.3M
Q4 24
$2.8B
$902.3M
Q3 24
$2.7B
$908.2M
Q2 24
$2.6B
$915.9M
Total Assets
IBOC
IBOC
NEO
NEO
Q1 26
$1.3B
Q4 25
$16.6B
$1.4B
Q3 25
$16.6B
$1.4B
Q2 25
$16.5B
$1.4B
Q1 25
$16.3B
$1.6B
Q4 24
$15.7B
$1.6B
Q3 24
$15.9B
$1.6B
Q2 24
$15.5B
$1.6B
Debt / Equity
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBOC
IBOC
NEO
NEO
Operating Cash FlowLast quarter
$491.1M
$-8.1M
Free Cash FlowOCF − Capex
$472.9M
FCF MarginFCF / Revenue
217.2%
Capex IntensityCapex / Revenue
8.3%
Cash ConversionOCF / Net Profit
4.59×
TTM Free Cash FlowTrailing 4 quarters
$809.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBOC
IBOC
NEO
NEO
Q1 26
$-8.1M
Q4 25
$491.1M
$1.3M
Q3 25
$115.2M
$8.9M
Q2 25
$95.5M
$20.3M
Q1 25
$140.5M
$-25.3M
Q4 24
$473.9M
$9.8M
Q3 24
$116.5M
$9.2M
Q2 24
$107.2M
$13.9M
Free Cash Flow
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
$472.9M
$-6.5M
Q3 25
$112.2M
$570.0K
Q2 25
$91.6M
$14.0M
Q1 25
$133.1M
$-29.8M
Q4 24
$459.8M
$-1.8M
Q3 24
$109.6M
$-1.6M
Q2 24
$104.9M
$814.0K
FCF Margin
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
217.2%
-3.4%
Q3 25
51.5%
0.3%
Q2 25
44.0%
7.7%
Q1 25
67.1%
-17.8%
Q4 24
220.8%
-1.0%
Q3 24
51.7%
-0.9%
Q2 24
50.5%
0.5%
Capex Intensity
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
8.3%
4.1%
Q3 25
1.3%
4.4%
Q2 25
1.9%
3.5%
Q1 25
3.7%
2.7%
Q4 24
6.8%
6.7%
Q3 24
3.3%
6.4%
Q2 24
1.1%
8.0%
Cash Conversion
IBOC
IBOC
NEO
NEO
Q1 26
Q4 25
4.59×
Q3 25
1.06×
Q2 25
0.95×
Q1 25
1.45×
Q4 24
4.12×
Q3 24
1.17×
Q2 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons